| Website | tearscience.com |
| Category | BioTech |
| Employees |
| TOTAL | $44.5M |
| VENTURE FUNDING TOTAL | $44.5M |
| Series C, 5/10 Essex Woodlands Health Ventures Investor Growth Capital General Catalyst Partners De Novo Ventures Spray Venture Partners Quaker BioVentures | $44.5M |
“TearScience’s technology provides the most significant advancement in the past few decades toward the treatment of patients with evaporative dry eye problems. Based on clinical results, TearScience’s products have the potential to dramatically improve the quality of life for these patients.”
